BIRC5 and non-small cell lung carcinoma: We have demonstrated that overexpression of BIRC5 resulted in resistance to afatinib in NSCLC, and BIRC5-specific inhibitors may reverse the resistant phenotype and promote cell death of lung cancer cells.